Biotechnology
HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering
Listing milestone positions HanchorBio to strengthen institutional visibility, advance itsFBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a globa...
2026-03-25 18:00
4421
VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
* Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 * A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment * Fully biological transplant eliminates need for immunosuppres...
2026-03-25 17:11
3735
From SCAN to SPARK: Galaxy Brain Scientific Enables a New Paradigm in Non-invasive, Personalized Precision Treatment for Parkinson's Disease
BEIJING, March 24, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature Neuroscience demonstrating that Deep Brain Stimulation (DBS) achieves therapeutic efficacy in Parkinson's disease...
2026-03-25 10:34
4128
Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis
SHANGHAI, March 24, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatm...
2026-03-25 08:08
5215
HKeyBio Launches HKEY-NHP-onChip™ 1.1: World's First NHP In Vitro Model for Autoimmune and Allergic Diseases
The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success. SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO specializing in...
2026-03-24 20:30
3336
WuXi Biologics Reports Record 2025 Annual Results
* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY * IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) * EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; ...
2026-03-24 19:44
4750
Origin Agritech Names Global Crop Biotechnology Expert Dr. Jian Zhang to Board of Directors; Welcomes Return of Dr. Z. James Chen as Chief Financial Officer
Appointments Reinforce Deep Technical Expertise in Biotech R&D and Capital Markets Leadership as Origin Advances Its Commercial Pipeline BEIJING, March 24, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, tod...
2026-03-24 19:30
2970
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized p...
2026-03-24 18:29
3805
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine
("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven
drug discovery company, today announced the launch ofPandaClaw, a
transformative new feature of thePandaOmics
2026-03-23 20:30
5175
Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announ...
2026-03-23 11:14
4899
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2026-03-23 08:00
3979
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day,
WuXi Biologics reaffirms its commitment to sustainability through responsible
operations and efficient, circular water‑use practices that reduce
environmental impact.
2026-03-22 09:30
4063
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
* Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet * WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-...
2026-03-21 19:26
7214
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised$787 million in financing rounds. The investment included participation by a group of leading global investors, including Dimen...
2026-03-20 19:30
5145
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its$11.5 billion acquisition by Merck and at Viridian Therapeutics -...
2026-03-19 20:30
6740
Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced thatChina's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has...
2026-03-19 20:10
5269
Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointmen...
2026-03-19 14:42
5304
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
* Largest-ever grant from RIGHT Foundation to accelerate Phase 1b clinical trial of RSV preventive antibody * Technology licensed from Gates MRI; early studies confirm suppression of RSV infection * Targeting global markets while addressing unmet needs in developing countries INCHEON, South...
2026-03-18 20:00
5428
Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy
TAIPEI and SAN DIEGO, March 17, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its first-in-class investigational drug Pidnarule...
2026-03-18 07:00
6821
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
SHANGHAI, March 16, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK)optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of n...
2026-03-17 09:00
3243
Week's Top Stories
Most Reposted
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 305 media titles]
2026-05-21 22:13
The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 286 media titles]
2026-05-27 09:16
Consistently recognised: Infobip named a Leader in Gartner® Magic Quadrant™ for CPaaS again
[Picked up by 281 media titles]
2026-05-21 16:31
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
[Picked up by 280 media titles]
2026-05-26 08:40
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
9207
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
8741
